Ilotycin Pharmacology, Pharmacokinetics, Studies, Metabolism - Erythromycin

Ilotycin Pharmacology, Pharmacokinetics, Studies, Metabolism - Erythromycin

CLINICAL PHARMACOLOGY

Microbiology Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms in vitro and in clinical infections:

Streptococcus pyogenes (group A (beta)-hemolytic)

Alpha-hemolytic streptococci (viridans group)

Staphylococcus aureus , including penicillinase-producing strains (methicillin-resistant staphylococci are uniformly resistant to erythromycin)

Streptococcus pneumoniae

Mycoplasma pneumoniae (Eaton Agent, PPLO)

Haemophilus influenzae (not all strains of this organism are susceptible at the erythromycin concentrations ordinarily achieved)

Treponema pallidum

Corynebacterium diphtheriae

Neisseria gonorrhoeae

Chlamydia trachomatis